Atara Biotherapeutics Inc. (NASDAQ:ATRA) saw a downside of -3.07% to close Thursday at $17.35 after subtracting -$0.55 on the day. The 5-day average trading volume is 930,981 shares of the company’s common stock. It has gained $18.35 in the past week and touched a new high 3 times within the past 5 days. An average of 771,550 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 720,994.
ATRA’s 1-month performance is 19.49% or $1.85 on its low of $14.58 reached on 09/09/21. The company’s shares have touched a 52-week low of $11.81 and high of $28.20, with the stock’s rally to the 52-week high happening on 02/08/21. YTD, ATRA has lost -8.81% or -$2.09 and has reached a new high 3 times. However, the current price is down -38.48%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Sep 22, 9 days have gone by since the last insider trading activity for Atara Biotherapeutics Inc. (ATRA). Newell Joe (Chief Operations Officer) most recently sold 10,500 shares at $17.00 per share on Sep 22. This transaction cost the insider $178,500. Chief Operations Officer, Newell Joe, sold 3,116 shares at a price of $15.61 on Sep 15. Then, on Aug 30, Chief Operations Officer Newell Joe sold 3,500 shares at a price of $15.00 per share. This transaction amounted to $52,500.
Atara Biotherapeutics Inc. (ATRA) has a trailing price-to-earnings (P/E) ratio of 33.74 for the broader industry and 32.28 for the sector, meaning that investors are optimistic about the stock’s future prospects. ATRA stock has a beta of 2.37. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 208.63 while the price-to-book (PB) in the most recent quarter is 4.97.
Atara Biotherapeutics Inc.’s quick ratio for the period ended June 29 was 4.40, with the current ratio over the same period at 4.40 meaning that ATRA stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00. The firm’s gross profit as reported stood at $2.45 million against revenue of $309.05 million.
The effectiveness of a company’s management is also important for investors when it comes to determining the potential profitability of the investment. Atara Biotherapeutics Inc.’s return on assets over the past 12 months stands at -64.20%, while its return on equity (ROE) trailing 12 months is -82.20%. In comparison, the average ROE for the broader industry over the past year is -36.91.
For the quarterly period ending June 29 this year, Atara Biotherapeutics Inc.’s cash and short-term investments amounted to $249.52 million against total debt of $12.18 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected ATRA to announce -$0.89 per share in earnings in its latest quarter, but it posted -$0.91, representing a -2.20% surprise. EBITDA for the quarter stood at more than -$81.19 million. ATRA stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 125.25 million, with total debt at $12.18 million. Shareholders hold equity totaling $84.76 million
Let’s look briefly at Atara Biotherapeutics Inc. (ATRA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 30 September was 68.22% to suggest the stock is trending Neutral, with historical volatility in this time period at 27.51%.
The stock’s 5-day moving average is $17.57, reflecting a +3.18% or $0.54 change from its current price. ATRA is currently trading +8.81% above its 20-day SMA, +26.10% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +34.51% and -24.13% respectively.
Stochastic %K and %D was 79.92% and 82.11% and the average true range (ATR) pointed at 0.75. The RSI (14) points at 68.34%, while the 14-day stochastic is at 72.26% with the period’s ATR at 0.73. The stock’s 9-day MACD Oscillator is pointing at 0.41 and 0.87 on the 14-day charts.
In the most recent analyst report for Atara Biotherapeutics Inc. (NASDAQ: ATRA), JP Morgan upgraded it to an Overweight rating. They previously had a Neutral rating on the stock. Analysts offering their rating for ATRA stock have a consensus rating for the stock as Buy. Currently, 1 brokerage advisors rate ATRA as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 9 have offered a “buy” rating.
What is ATRA’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $10.00 and a high of $78.00, with their median price target at $29.00. Looking at these predictions, the average price target given by analysts is for Atara Biotherapeutics Inc. (ATRA) stock is $33.38.